论文部分内容阅读
目的:探讨基质金属蛋白酶-9(MMP-9)和组织蛋白酶L(CL)在卵巢恶性肿瘤患者外周血中的表达及其与肿瘤侵袭和转移的关系。方法:采用酶连免疫吸附反应(ELISA)方法,检测67例卵巢恶性肿瘤患者、60例卵巢良性肿瘤患者和60例健康妇女血清中MMP-9和CL含量变化。结果:肿瘤患者血清MMP-9和CL水平显著高于正常对照组,相比较有统计学差异(P<0.05);且恶性肿瘤组患者血清MMP-9和CL水平显著高于良性肿瘤组(P<0.05)。上皮性肿瘤组患者血清MMP-9和CL水平显著高于非上皮性肿瘤组(P<0.05)。Ⅲ～Ⅳ期患者血清MMP-9和CL水平显著高于I～Ⅱ期患者(P<0.05)。淋巴结转移患者血清MMP-9和CL水平显著高于无淋巴结转移患者(P<0.05)。结论:MMP-9和CL在卵巢恶性肿瘤外周血中高表达,MMP-9和CL参与了卵巢恶性肿瘤的形成和发展。通过检测血清MMP-9和CL的含量变化可以为卵巢恶性肿瘤的干预和治疗提供参考。
Objective: To investigate the expression of matrix metalloproteinase-9 (MMP-9) and cathepsin L (CL) in peripheral blood of ovarian cancer patients and its relationship with tumor invasion and metastasis. Methods: Serum levels of MMP-9 and CL in 67 patients with ovarian cancer, 60 patients with benign ovarian tumor and 60 healthy women were detected by enzyme-linked immunosorbent assay (ELISA). Results: The levels of serum MMP-9 and CL in cancer patients were significantly higher than those in normal controls (P <0.05). The serum levels of MMP-9 and CL in patients with malignant tumors were significantly higher than those in benign tumors <0.05). The serum levels of MMP-9 and CL in patients with epithelial tumors were significantly higher than those in non-epithelial tumors (P <0.05). Serum levels of MMP-9 and CL in stage III-IV patients were significantly higher than those in stage I-II patients (P <0.05). Serum levels of MMP-9 and CL in patients with lymph node metastasis were significantly higher than those without lymph node metastasis (P <0.05). Conclusion: MMP-9 and CL are highly expressed in peripheral blood of ovarian cancer, and MMP-9 and CL are involved in the formation and development of ovarian cancer. Detection of serum levels of MMP-9 and CL can provide a reference for the intervention and treatment of ovarian cancer.